Publication | Closed Access

A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI – GINECO study

Single AgentMedicineCancer ManagementGynecologyPhase Ii StudyCancer TreatmentOncologyRadiation OncologyGynecology OncologyOvarian Cancer